长沙招聘

Job Purpose (State in a nutshell the overall objective of the role)
In charge of GL accounting of SNT, ensure month end close process. Deliver accurate and timely financial reports and full compliance with Company policies
Major Accountabilities (Describe the main results of the role to be achieved )
Month End closing
Ensure GL accounting accurate and in line with NAM.
Prepare Month end report in time and accurately.
Lead Monthly BS reconciliation, timely investigation and adjustment for incorrect items.
Account Payables
Review AP accountants’ daily work.
Account Receivables
Work with SD team, review sales billing n the SAP system
Review invoice to customers
Compliance
Back up FRA cycle owner in NFCM and compliance improvement
Support auditing coordination both internal and external
Other
Intercompany contact person and monthly intercompany reconciliation.
Key Performance Indicators / Measures of success
(Indicate how performance for this role will be measured)

?Timely and accurately for month closing
< 3 time error booking per NAM within one month
Month closing with in time table
?Comply VP4
?Comply SOP and MAL



Job Dimensions (Indicate key facts and figures)


People responsibilities /
Number of associates:0
Financial responsibility:
(Budget, Cost, Sales, etc.)
General ledger/ Financial Statements / Sales / intercompany
Decision boundaries:

Relationship in- and outside organisation:
?Sales team/SD team/HR team/3rd party Customers
?Other functional department, such as Financial Report-ing, Procurement, HR
?Accounting department of the associated companies
Thirty-party service providers, including external con-sultants, internal/external auditors and tax authorities

北京诺华制药有限公司开发、生产和销售治疗多种疾病的创新处方药，涵盖的疾病领域包括：心血管、内分泌、肿瘤、抗感染、风湿疼痛及骨质疏松、移植免疫、中枢神经以及眼科。北京诺华制药曾获得“***雇主”和“最负社会责任的企业”等殊荣。

“诺华”中文取意“承诺中华”，即承诺通过不断创新的产品和服务致力于提高中国人民的健康水平和生活质量。北京诺华制药成立于1987年，总部设在北京，隶属于瑞士诺华公司。

诺华公司致力于为患者及社会提供创新医药保健解决方案，以满足其日益变化的健康需求。2011年，集团持续经营业务实现净销售586亿美元。集团研发投入约为96亿美元（去除减值及摊销后为92亿美元）。诺华集团总部位于瑞士巴塞尔，业务遍及全球140多个国家和地区，拥有124,000位全职员工。诺华集团立足在中国的长期发展，重要战略投资包括位于上海的综合性生物医学研发中心，以及位于北京昌平的制剂生产工厂和江苏常熟的原料药生产工厂。如需更多信息，敬请登录公司网站http://www.novartis.com和http://www.novartis.com.cn。